Daniel Erskine
danielersk1ne.bsky.social
Daniel Erskine
@danielersk1ne.bsky.social
ARUK Senior Fellow and Senior Lecturer at Newcastle University. Interest in the neuropathology and biology of Lewy body diseases and related neurodegenerative diseases, particularly lysosomal storage disorders.
Views are my own.
Happy to have contributed to this fantastic study on associations between aSyn and DNA damage
New paper "supports the hypothesis of a reciprocal relationship between aSyn pathology & nuclear DNA damage & highlights a potential underlying role for DNA damage in pathological mechanisms relevant to dementia with Lewy body"
molecularneurodegeneration.biomedcentral.com/articles/10....
March 23, 2025 at 10:20 PM
Unbelievably proud to be an (honorary) geordie.

"Oh me lads, you shoulda seen us gannin..."

#ToonToon #HowayTheLads
March 16, 2025 at 7:35 PM
Reposted by Daniel Erskine
Early Possible Signs of Lewy Body Dementia:🔎 Start looking for early symptoms around ages 55-65, as LBD often develops between 50-85 years of age.

1️⃣ Cognitive changes: Fluctuating attention, alertness, or thinking ability
---
March 5, 2025 at 10:40 PM
A beautiful sky over #Newcastle at dusk tonight.
January 15, 2025 at 5:08 PM
Reposted by Daniel Erskine
Funded PhD position within the @alzsocresearch.bsky.social Lewy Body Dementia Doctoral Training Network at University of Southampton working to develop a novel experimental model of Dementia with Lewy bodies for testing therapeutic interventions.

www.dementiaresearcher.nihr.ac.uk/job/phd-nove...
January 13, 2025 at 4:37 PM
Great editorial from Hubert Fernandez on an important paper led by @albertoespay.bsky.social, to which I contributed a small amount, on the role of aSyn in #Lewy body diseases. Open-mindedness is key, none of us have all the answers and we all have the same goal.

www.prd-journal.com/article/S135...
The Alpha Synuclein Tug of War: A Call for Academic Civility and Open-mindedness
My dear colleagues, this month’s issue of Parkinsonism and Related Disorders features a Point of View paper by Espay et al entitled, “The α-Synuclein Seed Amplification Assay: Interpreting a Test of Parkinson’s Pathology” [1]. In this article, the authors caution those who jump on the synuclein bandwagon all too quickly. They present their viewpoints regarding the weaknesses of using alpha synuclein seed amplification assay (αSyn-SAA) as a basis for the biological staging of Parkinson disease (PD).
www.prd-journal.com
January 8, 2025 at 9:14 PM
Hello everyone, happy to share my first post here on BSky. I've moved over from Twitter and looking forward to seeing and discussing interesting science here. Please give me a follow if you're interested in #Lewy body diseases or #lysosomal storage disorders.
Thank you!
December 8, 2024 at 7:23 PM
Reposted by Daniel Erskine
First podcast experience! I was delighted to be a guest on the North of Scotland Parkinson’s Research Podcast to raise awareness of #delirium in #Parkinsons. Have a listen here or wherever you get your podcast open.spotify.com/episode/7DoI...

@nihrnewcastlebrc.bsky.social @newcastleuni.bsky.social
Delirium in Parkinson's - Dr Rachael Lawson, Senior Research Fellow and Senior Lecturer, University of Newcastle
open.spotify.com
November 21, 2024 at 6:25 PM